Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Oral Budesonide Suspension (OBS) in Adolescent and Adult Subjects (11 to 55 Years of Age, Inclusive) With Eosinophilic Esophagitis: A Phase 3 Randomized, Double-blind, Placebo-controlled Study

Next Previous
Trial Profile

Oral Budesonide Suspension (OBS) in Adolescent and Adult Subjects (11 to 55 Years of Age, Inclusive) With Eosinophilic Esophagitis: A Phase 3 Randomized, Double-blind, Placebo-controlled Study

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 15 Feb 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Budesonide (Primary)
  • Indications Eosinophilic oesophagitis
  • Focus Registrational; Therapeutic Use
  • Acronyms ORBIT1
  • Sponsors Shire; Takeda

Most Recent Events

  • 12 Feb 2024 According to a Takeda media release, based on results from study 1(NCT02605837) and study 2(NCT01642212), the FDA has approved EOHILIA (budesonide oral suspension), for people 11 years and older with eosinophilic esophagitis (EoE).
  • 01 Dec 2023 Results of pooled post hoc analysis (n=76 from studies NCT01642212 and NCT02605837) assessing efficacy and safety of budesonide oral suspension (BOS) in adolescents with eosinophilic esophagitis published in the Journal of Pediatric Gastroenterology and Nutrition
  • 20 Sep 2023 According to a Takeda media release, company announced that USFDA that the U.S. Food and Drug Administration (FDA) has accepted for review its New Drug Application (NDA) resubmission for TAK-721 (budesonide oral suspension) which is being investigated for the short-term treatment of eosinophilic esophagitis and company expects a decision from the FDA during the first half of 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top